Teva Reports Results from the P-III Study of Ajovy (fremanezumab) to Prevent Migraine in Chinese Patients
Shots:
- The P-III trial investigates the safety, efficacy and tolerability of Ajovy (225mg, once-monthly for 3mos. or 675mg single dose, once-quarterly, SC) injection vs PBO as a treatment of Chinese patients (n=365, 18-70yrs.) with episodic or chronic migraine
- The study demonstrated a reduction in the monthly migraine days and reached the 2EPs of measures for early efficacy within the first month, responder rate analysis (50% reduction of migraine days) & decreased use of acute headache medication over 3mos. post-initiation
- The drug was well-tolerated without any emerging safety signals and the safety profile aligned with the prior P-III studies for treating migraine
Ref: Teva | Image: Teva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
